Best sellerBPC-157 Guide
$14BPC-157: mechanism, reported effects, commonly cited dosage ranges, reconstitution math and named stacks — gastrointestinal and tissue-repair research.
Free US shipping for orders above $200
Educational Library
Peptide Guide Library — Educational Peptide Guides & Dosing Reference Charts
A growing library of 55 educational peptide guides and dosing reference charts, with beginner-first walkthroughs, research-context interpretation notes, and practical learning tools.
55 educational peptide guide topics availableCompliance-reviewed educational copyAll-Access Lifetime unlocks the entire library — current and future guides
55 popular peptide guide topics
Single-Guide Access
$14
Any available guide
All-Access Lifetime
$99
All guides — current + future library
Best selling peptide guides
Start with the most popular educational guides in the library, then explore the rest of the catalog below.
Best seller
Best sellerGHK-Cu Guide
$14Free GHK-Cu guide for skin, tissue, and cosmetic research: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
Best sellerTB-500 Guide
$14TB-500 explained — mobility and soft-tissue research. Evidence status, reported dosage ranges, reconstitution math, storage and named stacks.
Best sellerCJC-1295 Guide
$14CJC-1295: mechanism, reported effects, commonly cited dosage ranges, reconstitution math and named stacks — growth-hormone-axis research.
More peptide guides
Explore the full peptide guide library. Every guide follows the same educational format and can be purchased individually.
Ipamorelin Guide
$14Free Ipamorelin guide: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
Semaglutide Guide
$14Semaglutide explained — metabolic and GLP-1 research. Evidence status, reported dosage ranges, reconstitution math, storage and named stacks.
Tirzepatide Guide
$14Tirzepatide: mechanism, reported effects, commonly cited dosage ranges, reconstitution math and named stacks — metabolic and incretin research.
Retatrutide Guide
$14Free Retatrutide guide: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
Tesamorelin Guide
$14Tesamorelin explained — body-composition and endocrine research. Evidence status, reported dosage ranges, reconstitution math, storage and named stacks.
Sermorelin Guide
$14Sermorelin: mechanism, reported effects, commonly cited dosage ranges, reconstitution math and named stacks — growth-hormone-axis research.
Thymosin Alpha-1 Guide
$14Free Thymosin Alpha-1 guide for immune research: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
PT-141 Guide
Free to readPT-141 explained — melanocortin research. Evidence status, reported dosage ranges, reconstitution math, storage and named stacks.
Oxytocin Guide
$14Oxytocin: mechanism, reported effects, commonly cited dosage ranges, reconstitution math and named stacks — social-bonding and reproductive research.
Epithalon Guide
$14Free Epithalon guide for cellular-aging research: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
KPV Guide
$14KPV explained — skin, gut, and inflammatory research. Evidence status, reported dosage ranges, reconstitution math, storage and named stacks.
Selank Guide
Free to readSelank: mechanism, reported effects, commonly cited dosage ranges, reconstitution math and named stacks — neurocognitive research.
Semax Guide
$14Free Semax guide for neurocognitive research: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
DSIP Guide
$14DSIP explained — sleep and neuroendocrine research. Evidence status, reported dosage ranges, reconstitution math, storage and named stacks.
Kisspeptin-10 Guide
$14Kisspeptin-10: mechanism, reported effects, commonly cited dosage ranges, reconstitution math and named stacks — reproductive-axis research.
ARA-290 Guide
Free to readFree ARA-290 guide: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
5-Amino-1MQ Guide
Free to read5-Amino-1MQ explained — metabolic research. Evidence status, reported dosage ranges, reconstitution math, storage and named stacks.
MOTS-c Guide
Free to readMOTS-c: mechanism, reported effects, commonly cited dosage ranges, reconstitution math and named stacks — mitochondrial and metabolic research.
SS-31 Guide
$14Free SS-31 guide: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
IGF-1 LR3 Guide
$14IGF-1 LR3 explained — growth-factor and anabolic-signaling research. Evidence status, reported dosage ranges, reconstitution math, storage and named stacks.
Glutathione Guide
$14Glutathione: mechanism, reported effects, commonly cited dosage ranges, reconstitution math and named stacks — oxidative-stress and detoxification research.
SLU-PP-332 Guide
Free to readFree SLU-PP-332 guide: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
GHRP-2 Guide
Free to readGHRP-2 explained — growth-hormone-secretagogue and ghrelin-receptor research. Evidence status, reported dosage ranges, reconstitution math, storage and named stacks.
GHRP-6 Guide
Free to readGHRP-6: mechanism, reported effects, commonly cited dosage ranges, reconstitution math and named stacks — growth-hormone-secretagogue and appetite-signaling research.
Melanotan II Guide
Free to readFree Melanotan II guide: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
Mod GRF 1-29 (CJC-1295 No DAC): Dosage, Reconstitution and Reading a Test Report
$14Mod GRF 1-29 / CJC-1295 no DAC: the only human CJC-1295 study tested the DAC version at 60-90 mcg/kg, the unmeasured half-life, unit math, and what a purity report can establish.
NA-Semax Amidate Guide
Free to readNA-Semax Amidate: mechanism, reported effects, commonly cited dosage ranges, reconstitution math and named stacks — neuroprotective and cognitive-signaling research.
N-Acetyl Selank Amidate: COA, Purity and the Mass That Tells It From Selank
$14N-Acetyl Selank Amidate: the +41 Da mass difference a certificate of analysis must show, why purity cannot establish identity, the salt-form correction to every concentration, and the two figures this page retracted.
Gonadorelin Guide
Free to readGonadorelin explained — hypothalamic-pituitary-gonadal (HPG) axis research. Evidence status, reported dosage ranges, reconstitution math, storage and named stacks.
Cagrilintide: Dosage in Units, Reconstitution Chart and the 2026 Phase 3 Record
$14Cagrilintide: the dosing chart in insulin-syringe units, the sourced 159-195 hour half-life, and what the 2026 REIMAGINE and REDEFINE phase 3 trials measured — including the 0.16-point HbA1c result.
NAD+ Guide
Free to readFree NAD+ guide: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
LL-37 Guide
Free to readLL-37 explained — antimicrobial, wound-repair, and immune-modulation research. Evidence status, reported dosage ranges, reconstitution math, storage and named stacks.
Cartalax Guide
Free to readCartalax (AED, Ala-Glu-Asp): the sequence it is actually indexed under, what its six published cell-culture studies tested, reported dosage ranges, reconstitution math and named stacks.
Thymalin Guide
Free to readFree Thymalin guide for thymic and immune-modulation research: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
Thymulin Guide
Free to readThymulin (FTS-Zn): the zinc-dependent thymic nonapeptide — how it differs from Thymalin, what the two double-blind human trials actually found, published trial doses, reconstitution math and storage.
MGF (Mechano Growth Factor): Dosage, Reconstitution and the Replication That Failed
$14MGF, the IGF-1Ec E-peptide: two pharmaceutical companies could not reproduce its claimed effect, no half-life has ever been measured, and the active research on it is oncology. PEG-MGF has its own guide.
Follistatin 344 Guide
Free to readFollistatin 344: mechanism, reported effects, commonly cited dosage ranges, reconstitution math and named stacks — myostatin-inhibition and muscle-mass research.
Hexarelin Guide
$14Free Hexarelin guide: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
VIP Guide
$14VIP explained — immune-modulation and inflammatory research. Evidence status, reported dosage ranges, reconstitution math, storage and named stacks.
PE-22-28 Guide
Free to readPE-22-28: mechanism, reported effects, commonly cited dosage ranges, reconstitution math and named stacks — TREK-1 channel and mood/neurogenesis research.
AHK-Cu Guide
Free to readFree AHK-Cu guide: how it works, what studies report, reported dosage ranges, half-life, side effects and reconstitution math.
Melanotan I Guide
$14Melanotan I explained — melanocortin and skin-pigmentation research. Evidence status, reported dosage ranges, reconstitution math, storage and named stacks.
AOD-9604: The Failed Phase 2b, Dosage, Reconstitution and Regulatory Status
$14AOD-9604: the confirmatory Phase 2b that missed its endpoint, why every human trial was oral or IV, reported dosage, reconstitution math and stacks.
HGH Fragment 176-191: Foundational Research Guide
$14HGH Fragment 176-191: what its own cited sources actually show, how it differs from AOD-9604 and the 177-191 sequence, dosage and reconstitution math.
Pinealon (EDR Peptide) Foundational Guide
$14Pinealon (EDR): the Khavinson short-peptide literature and who produced it, the rodent-to-human dose gap, reported dosage and reconstitution math.
Dihexa (PNB-0408): Critical Evidence Review
$14Dihexa: the retracted literature behind the nootropic claims, the unresolved tumour-growth concern, why it needs DMSO rather than bacteriostatic water.
PEG-MGF (PEGylated Mechano Growth Factor)
$14PEG-MGF: what PEGylation does and does not change, the unmeasured half-life claim, the vendor non-standardisation problem, and reconstitution math.
Cerebrolysin: Trial Dosage, the CASTA Null Result and Why Nothing Here Is Reconstituted
$14Cerebrolysin: a porcine brain hydrolysate, not a peptide — the trial infusion regimens, the 1,070-patient CASTA null result, Cochrane's dose-linked adverse-event finding, and why no reconstitution math applies.
Mazdutide (IBI362, LY3305677) Guide: Trial Doses, the 9 mg Trade-Off and Reconstitution
Free to readMazdutide (IBI362 / LY3305677): the glucagon/GLP-1 dual agonist approved in China in 2025 — the 4 mg, 6 mg and 9 mg phase 3 doses, what 9 mg cost in adverse events, and the reconstitution math.
Survodutide (BI 456906) Guide: Dosage, Titration and the Phase 3 Evidence
$14Survodutide (BI 456906): the investigational glucagon/GLP-1 dual agonist — what SYNCHRONIZE-1 reported at 3.6 mg and 6.0 mg weekly, the months-long titration, and the reconstitution math.
P11-4 (Curodont, Oligopeptide-104): The Self-Assembling Dental Peptide, Explained
Free to readP11-4 (Curodont, oligopeptide-104): a self-assembling dental enamel biomaterial — applied to a tooth surface rather than injected, and not systemic.
Cross-compound guides
Two standalone guides cover the material that does not belong to any single compound — how combinations are constructed, and how the bloodwork that measures them is read. Both are included with All-Access Lifetime.
Standalone guidePeptide Stacking Guide
$39The cross-compound stacking reference: the named blends, which pairings are redundant rather than additive, where interaction risk is documented versus merely unstudied, and the blend arithmetic.
Standalone guidePeptide Blood Marker Guide
$39Which blood markers matter on peptides, how each one is read against your own baseline rather than a population range, and the marker map for every compound in the library.
Choose Your Access
Choose single-guide access for any currently available guide or library-wide lifetime access that includes current and future guide releases.
Single-Guide Standard Access
$14
Access to one guide topic at a time. Quick-add is shown below for available guides.
- The full guide page free to read, for every compound
- That compound’s Evidence File, Sourcing File and Benefit & Outcome Review
- That compound’s Stacking Module
All-Access Lifetime
$99
Library-wide access to all 55 guides — current and future releases — plus downloadable resources.
- Every guide in the library — all 55 topics unlocked
- Current and future library guide releases included
- Downloadable PDF reference bundle
- Printable worksheet pack for offline use
How The Library Is Structured
The library uses a repeatable twelve-section format for each guide: what the compound is and how it works, the effects and side effects reported in research, evidence and regulatory status, the dosage ranges commonly cited, reconstitution math with a built-in calculator, half-life, named stacks, storage, and the references behind it all.
Sections 1–4
What it is and how it works
The compound, its mechanism, the effects reported in research, and its evidence and regulatory status.
Sections 5–8
The practical numbers
Dosage ranges commonly cited in research, reconstitution math with a built-in calculator, administration basics and half-life — examples of what is reported, not instructions.
Sections 9–12
Cautions, stacks and sources
Reported side effects, named stacks, storage, and the source references — the same structure across all 55 guides.
Peptide Dosing Reference Chart — All 55 Compounds
A free reference chart covering every compound in the library in one table — no account, no download required. Each row shows the range commonly reported for that compound and its plasma half-life, with a link through to the full guide and to a free reconstitution calculator. The rows are generated from the guide content itself rather than maintained as a separate table, so the chart cannot contradict the pages it summarises; where a cell shows a dash, the figure is stated on the guide page in a form this table cannot condense, and the guide is the reference.
Two things to read carefully. These are examples of what is reported in published research and community sources — they are not recommendations, not personal-use instructions, and not a dose for any person. And where no published human pharmacokinetic study exists, the half-life column says so rather than repeating a figure that circulates without a source; several widely quoted peptide half-lives have never been measured in humans.
| Compound | Commonly reported range (example, not a recommendation) | Plasma half-life | Guide |
|---|---|---|---|
| 5-Amino-1MQ | Community sources describe oral doses of roughly 50–150 mg per day — anecdotal, not derived from any human study. Mouse efficacy work used 10 and 32 mg/kg/day subcutaneously. | Measured in mice in 2024, not in humans: terminal half-life 6.3 h after intravenous dosing, 12.8–13.3 h subcutaneous, 14.8 h oral. | 5-Amino-1MQ guide |
| AHK-Cu | Topical: 2-5% scalp serum; subcutaneous (community-reported): ~50-200 mcg daily | Not formally established in humans; small copper-peptide complexes are believed to clear rapidly | AHK-Cu guide |
| AOD-9604 | 250-500 mcg/day subcutaneously (~300 mcg the modal figure) — no published human trial or pharmacokinetic study supports this route or dose | — | AOD-9604 guide |
| ARA-290 | Phase 2 trials tested 1, 4 and 8 mg daily by subcutaneous injection; 4 mg met the primary endpoint | Very short - reported on the order of minutes | ARA-290 guide |
| BPC-157 | ~250–500 mcg per day (community-reported; some report split AM/PM dosing). | Reported under 30 minutes. | BPC-157 guide |
| Cagrilintide | 0.16, 0.30, 0.60, 1.2, 2.4 and 4.5 mg once weekly in phase 1b dose-ranging; 1.0 mg and 2.4 mg once weekly are the two doses carried into the 2026 phase 3 program. | 159-195 hours (about 6.6-8.1 days) across 0.16-4.5 mg, with median tmax 24-72 hours. | Cagrilintide guide |
| Cartalax | Roughly 1–2 mg/day subcutaneous or 10–20 mg/day oral in community write-ups. These figures trace to vendor and forum sources, not to any published study — no published work has administered… | Not established in any species. No pharmacokinetic study of AED has been published, so there is no measured half-life, clearance or bioavailability… | Cartalax guide |
| Cerebrolysin | The trial regimens, all intravenous: 30 mL/day in 100 mL saline for 10 days (stroke, the CASTA regimen); 50 mL/day for 10 days then two cycles of 10 mL/day (CAPTAIN, TBI); | Not established, and arguably not a well-formed question for a mixture. PubMed records pairing cerebrolysin with pharmacokinetics or half-life are… | Cerebrolysin guide |
| CJC-1295 | DAC form — 30, 60 and 90 mcg/kg as single subcutaneous injections across two trials (PMID 16352683, PMID 17018654) — roughly 2,100, 4,200 and 6,300 mcg for a 70 kg adult. | DAC form: 5.8-8.1 days (PMID 16352683). No-DAC form: no published human measurement — see below. | CJC-1295 guide |
| Dihexa | Community and grey-market reports cluster at 5-10 mg daily described as "low" and 10-20 mg daily described as "moderate", for 4-8 weeks. | — | Dihexa guide |
| DSIP | Community sources describe roughly 100-250 mcg subcutaneously before bed; the human trials instead used about 25 nmol/kg intravenously. | Reported at roughly 7-15 minutes in early intravenous human work — very short, and a poor match for a compound expected to act across a night. | DSIP guide |
| Epithalon | Community examples of roughly 5-10 mg per day for short courses (no established human dose) | Very short - minutes; no established human pharmacokinetic profile | Epithalon guide |
| Follistatin 344 | Community-reported figures cluster around 100 mcg per administration. There is no trial dose to report because no published trial has injected follistatin protein into a human — the figures… | No published pharmacokinetic study of injected, unmodified follistatin in humans could be located. | Follistatin 344 guide |
| GHK-Cu | Topical formulations commonly 0.05-2%; injectable research examples around 1-2 mg per administration (no established human dose) | Short - GHK is cleared rapidly from plasma; no well-established human half-life for the copper complex | GHK-Cu guide |
| GHRP-2 | 100-300 mcg per injection (community-reported examples) | Approximately 1-2 hours (GH pulse peaks 15-30 minutes post-dose) | GHRP-2 guide |
| GHRP-6 | 100-300 mcg per injection (community-reported saturation dose ~1 mcg/kg) | Reported ~15-20 minutes (short); some sources cite a terminal phase up to ~2.5 hours | GHRP-6 guide |
| Glutathione | Community injection reports describe ~200-600 mg per session, 1-3x weekly. The doses with data behind them are 1,400 mg IV three times weekly (Parkinson's trial, null result) and 250-500 mg… | Measured at 14.1 +/- 9.2 minutes in 10 healthy volunteers after a 2 g/m2 intravenous infusion (Eur J Clin Invest 1991) | Glutathione guide |
| Gonadorelin | ~50-200 mcg per injection in community and research reports (not a recommendation) | Very short: ~2-10 min distribution, ~10-40 min terminal | Gonadorelin guide |
| Hexarelin | 100-200 mcg per subcutaneous injection is the range described in community sources (not a recommendation, and not what the trials used) | Reported at roughly 55-80 minutes — a figure that circulates widely but is not stated in the abstracts of the human trials most often cited for it | Hexarelin guide |
| HGH Fragment 176-191 | 250-500 mcg per injection in community settings; 250 mcg is the near-universal reported starting point. | — | HGH Fragment 176-191 guide |
| IGF-1 LR3 | ~20-100 mcg per day in community write-ups. No validated human dose exists and no dose-finding study has ever been run | Not established in humans. The widely repeated "20-30 hours" is unsourced and points the wrong way - see the half-life section, where the FDA label… | IGF-1 LR3 guide |
| Ipamorelin | ~100–300 mcg per dose (community-reported). | Reported ~2 hours. | Ipamorelin guide |
| Kisspeptin-10 | Published human work used intravenous infusion, e.g. 1.5 mcg/kg/h in George et al. 2011; community-reported subcutaneous figures (~50-200 mcg) are anecdotal and have no trial behind them. | No established human figure. In vitro the peptide decomposes with a half-life of 1.7 min at 37 C (Liu 2013); | Kisspeptin-10 guide |
| KPV | Roughly 250-500 mcg per day subcutaneously, sometimes split into two administrations; oral protocols are discussed at milligram amounts. | No published human pharmacokinetic study reports one. The figures circulating on commercial pages are not traceable to a measurement. | KPV guide |
| LL-37 | ~100–500 mcg per administration in community reports (no established human protocol) | Short; estimated on the order of ~1 hour, highly dependent on proteolysis | LL-37 guide |
| Mazdutide | 4 mg and 6 mg once weekly in GLORY-1 and in both DREAMS phase 3 trials; 9 mg once weekly in GLORY-2; 3 mg, 4.5 mg and 6 mg in the phase 2 programme; a 32-person phase 1 escalated to 16 mg. | Not established in the indexed literature. A PubMed search pairing mazdutide — or either development code, which return the same record set — with… | Mazdutide guide |
| Melanotan I | One 16 mg implant, repeated every 60 days in the pivotal trials — a solid, white to off-white, bioresorbable sterile rod approximately 1.7 cm long and 1.45 mm in diameter, inserted… | No published figure for injected melanotan 1 — the compound was developed as a controlled-release implant, so the pharmacokinetics that were… | Melanotan I guide |
| Melanotan II | ~250–500 mcg per dose in community reports | Reported short, roughly 30 minutes to ~1 hour | Melanotan II guide |
| MGF | 200-400 mcg per injection in community reports, with a wider span of roughly 100-600 mcg. No trial of any kind establishes a dose for this peptide. | Never measured. No published pharmacokinetic study reports a half-life for the MGF E-peptide in any species. | MGF guide |
| Mod GRF 1-29 | ~100 mcg per injection is the figure the market repeats as a 'saturation dose'; reported protocols span roughly 100-300 mcg. No trial establishes this range for the no-DAC peptide. | No measured value has been published for this peptide. The ~30 minutes commonly quoted is an inference from DPP-IV resistance, not a measurement; | Mod GRF 1-29 guide |
| MOTS-c | Roughly 5-10 mg per administration in research-community discussion, with no published human dose behind it. | — | MOTS-c guide |
| NA-Selank Amidate | ~250–900 mcg per day in divided applications, intranasal, from community sources rather than from any trial. | Not established; the widely repeated "20–30 minutes" is leu-enkephalin's half-life, not Selank's, and is withdrawn here. | NA-Selank Amidate guide |
| NA-Semax Amidate | Roughly 300–900 mcg per day in vendor and community protocols, often split across one to three administrations. | Not established for the analog, and poorly established for Semax itself. The one indexed measurement — Semax incubated with rat brain plasma… | NA-Semax Amidate guide |
| NAD+ | 50-100 mg subcutaneous per injection (community-reported); higher amounts reported for IV in clinical settings. | Short; serum half-life reported under ~1 hour, with rapid intracellular uptake. | NAD+ guide |
| Oxytocin | Intranasal research most often uses 24 IU per administration; the largest trial used 48 IU daily. Research-vial reports describe roughly 100-200 mcg. No validated non-obstetric dose | About 1 to 6 minutes per the FDA-approved label, decreased further in late pregnancy and during lactation | Oxytocin guide |
| P11-4 | — | Not established, and not a meaningful parameter for this compound. There is no human pharmacokinetic data because it is never given systemically. | P11-4 guide |
| PE-22-28 | 50-200 mcg per administration is what circulates in community and vendor material. No human dose exists. | Not established for PE-22-28 in any species. The frequently quoted '23 hours' is NOT a half-life and is NOT PE-22-28 — it is a half-time of… | PE-22-28 guide |
| PEG-MGF | 200-400 mcg per administration in community and research-setting reports. No dose has ever been established in any species for the PEGylated form. | — | PEG-MGF guide |
| Pinealon | 1-2 mg once daily subcutaneously (a minority report 5-10 mg/day); oral capsules approximately 1-20 mg/day in the Khavinson consumer line. | — | Pinealon guide |
| PT-141 | 1.75 mg subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. | Approximately 2.7 hours, with a reported range of 1.9 to 4.0 hours. Tmax is about 1 hour. These are measured label values, not estimates. | PT-141 guide |
| Retatrutide | Phase 2 escalated to 12 mg once weekly; the published phase 3 used fixed 4 mg, 9 mg and 12 mg arms (reported, not an established dose). | No numeric half-life appears in the published phase 1 abstract; it reports a PK profile 'supporting once-weekly dosing' and a weight effect… | Retatrutide guide |
| Selank | Research and community examples of roughly 250-500 mcg per administration (no established Western dose) | No primary pharmacokinetic study establishing a plasma half-life for Selank was located in any species; | Selank guide |
| Semaglutide | Label escalation 0.25 to 2.4 mg once weekly (Wegovy); maintenance 1.7 or 2.4 mg once weekly | Approximately 1 week (elimination half-life about 155 hours) | Semaglutide guide |
| Semax | Community figures cluster around 300-600 mcg per administration; the registered Russian product is a 0.1% or 1% intranasal drop, dosed in drops rather than by weight. | Minutes. The Pro-Gly-Pro tail slows degradation relative to the bare ACTH fragment but does not make it long-lived. | Semax guide |
| Sermorelin | 30 micrograms per kilogram per day, subcutaneously at bedtime, in growth-hormone-deficient children. | Very short and properly measured: an initial phase of about 1.9 +/- 0.2 minutes and an elimination phase of about 10.4 +/- 0.2 minutes for… | Sermorelin guide |
| SLU-PP-332 | No human dose is established. There is no human pharmacokinetic study, no dose-response data and no bioavailability figure for any route in humans. | Unknown in humans — no human pharmacokinetic study of SLU-PP-332 has been published, so any specific human figure is unsourced. | SLU-PP-332 guide |
| SS-31 | 40 mg subcutaneously once daily, at the same time each day, in patients weighing at least 30 kg; reduced in severe renal impairment. | The label does not state one. It gives Tmax, bioavailability, distribution, metabolism and complete urinary recovery by 48 hours, but no elimination… | SS-31 guide |
| Survodutide | The doses with phase 3 data behind them are 3.6 mg and 6.0 mg subcutaneously once weekly, each reached by titration from 0.3 mg. | Consistent with once-weekly dosing, but we could not source a specific published half-life figure from the trial reports checked. | Survodutide guide |
| TB-500 | Roughly 2-5 mg per administration during a reported loading phase, then a lower weekly figure. These are community-reported numbers with no human dose-finding study behind them - the trial… | No published human half-life exists for the fragment. Figures of roughly 2-3 hours circulating online belong to the parent protein, and the new… | TB-500 guide |
| Tesamorelin | Label 1.28–2 mg/day across Egrifta formulations; off-label reports ~1–2 mg/day (examples, not recommendations). | 8 min (Egrifta SV) / 11 min (Egrifta WR) per label; ~26–38 min reported for the original formulation. | Tesamorelin guide |
| Thymalin | 5-10 mg per day (community and Russian clinical protocols); reconstitution here is concentration math only, not a personal dose. | Not well characterized; individual peptide fractions are reported to clear rapidly (minutes to a few hours), while biological effects are reported to… | Thymalin guide |
| Thymosin Alpha-1 | 1.6 mg subcutaneously twice weekly. This is the figure used in registered trials, not a recommendation. | Approximately 2 hours, with peak serum concentration within 2 hours and levels back to baseline within 24 hours (Ancell et al., 2001). | Thymosin Alpha-1 guide |
| Thymulin | 1, 5 and 10 mg/day were compared in the RA trials, with 5 mg/day the most effective arm. These are published trial figures, not recommendations. | Not established — no published human pharmacokinetic study reports a half-life figure for thymulin. | Thymulin guide |
| Tirzepatide | Label starts at 2.5 mg once weekly; maintenance doses are 5, 10 or 15 mg once weekly | Approximately 5 days (about 117 hours) | Tirzepatide guide |
| VIP | Community intranasal protocols report 50 mcg per nostril up to 4x daily (~400 mcg/day); subcutaneous examples of 25-100 mcg once daily. | Consistently described as very short, which is why every trial infused it rather than injecting a bolus. | VIP guide |
Most of these are supplied as a lyophilized powder, and reconstituting those requires bacteriostatic water and the concentration arithmetic that goes with it — concentration in mg/mL is the vial's milligram content divided by the millilitres added. A few are not reconstituted at all and say so on their own pages. Use the free dosage calculator or buy USP-grade bacteriostatic water.
FAQ
What is included in a Medibact peptide guide?
Every guide follows the same twelve-section structure: what the compound is, how it works, the effects reported in research, evidence and regulatory status, the dosage ranges commonly cited in studies and practice, reconstitution math with a built-in calculator, administration basics, half-life, reported side effects, named stacks, storage, and the source references. Single-guide access adds that compound's Evidence File, Sourcing File and Benefit & Outcome Review; All-Access adds those for every compound plus the printable protocol sheets. Guides are educational reference material — the dosage figures are examples of what is reported, not personal-use instructions.
Is there a downloadable peptide dosing chart or PDF?
The printable Protocol Sheet and Injection Log — reconstitution reference, reported example protocol, injection basics, common stacks and storage — come with All-Access Lifetime, which covers every compound in the library plus future releases. Single-guide access is the written depth for one compound: its Evidence File, Sourcing File and Benefit & Outcome Review.
How many peptides does the guide library cover?
55 peptide guide topics today, covering compounds such as BPC-157, TB-500, GHK-Cu, CJC-1295, Semaglutide, Tirzepatide, and Retatrutide. All-Access Lifetime also includes future guide releases as the library grows.
What's the difference between single-guide access and All-Access Lifetime?
Single-guide Standard Access unlocks one compound's three paid files: the Evidence File, the Sourcing File and the Benefit & Outcome Review. All-Access Lifetime unlocks those for the entire library — current and future guides — plus the downloadable PDF reference bundle and printable worksheet pack.
Do these guides provide personal dosing instructions?
No. Guides are educational, research-context reference material only. They do not provide personal-use dosing, administration, or protocol instructions.
Is there a free peptide dosing chart on this page?
Yes — the reference chart above is free, needs no account, and covers all 55 compounds in the library in a single table, listing the commonly reported range and the plasma half-life for each with a link through to the full guide. It is generated from the same guide content rather than maintained separately, so it cannot contradict the individual pages; a dash means the figure is stated on the guide page in a form the table cannot condense. The figures are examples of what is reported in research and community sources, not personal-use instructions.
What is a peptide half-life and why is it in the chart?
A half-life is the time taken for the concentration of a compound in plasma to fall by half, and it is the single figure that most shapes how a compound is studied — it is the reason sermorelin, cleared in about ten minutes, was trialled as a once-daily bedtime injection while a long-acting analog is not. It is included in the chart because it is the most frequently searched-for and most frequently mis-stated figure in this category. Where no human pharmacokinetic study exists, the chart says so rather than repeating a number that circulates without a source.
How do you calculate a peptide dose from a reconstituted vial?
Concentration in mg per mL equals the vial's milligram content divided by the millilitres of bacteriostatic water added; syringe units then equal (target amount ÷ concentration) × 100, because a 1 mL U-100 insulin syringe is graduated into 100 units across one millilitre. A 10 mg vial mixed with 2 mL gives 5 mg/mL, so a 5 mg amount is 100 units — a full syringe. Medibact publishes a free standalone calculator page for 51 of the 55 compounds in the library; the exceptions are the ones that are not reconstituted at all. This is concentration arithmetic, not dosing guidance.
Are the guides based on published research or on community reports?
Both, and each guide distinguishes them explicitly rather than blending them. Where an FDA-approved label exists — as it does for SS-31 (Forzinity), PT-141 (Vyleesi) and tesamorelin (Egrifta) — the approved dose, pharmacokinetics and adverse-reaction table are taken from the label and cited as such. Where trial data exists without approval, the guide cites the trial, including negative and terminated ones. Where only community reports exist, the guide says that plainly and explains where the figures came from. Several guides state that no published human half-life exists rather than repeating an unsourced number.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.